Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer
To identify the proportion of patients remaining medically castrated (testosterone level < 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.
Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer
- 29 August 2024 - 1 mins read
To identify the proportion of patients remaining medically castrated (testosterone level < 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.
Related Clinical Trials
29 August 2024
1 mins read
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
29 August 2024
1 mins read
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic...
29 August 2024
1 mins read
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
29 August 2024
1 mins read
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
29 August 2024
1 mins read
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
29 August 2024
1 mins read
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
29 August 2024
1 mins read
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
29 August 2024
1 mins read
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
29 August 2024
1 mins read
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
29 August 2024
1 mins read